We are entirely
not-for-profit

We at Brightwater believe that our only ‘metric’ is the QUALY. We are entirely not-for-profit and if we are successful in the development of a new therapeutic approach to Ewing, it may very well be possible that other rare cancers can be treated using the same or similar drugs – one example is malignant nonseminoma, but there may be others.

This is because there is an overlap in both current treatment regimens and gene expression sub-set data that makes it plausible that Valoxydin has wider applications.

Learn About Our Research

Brightwater Research is in the late stages of developing a new drug to stop the spread of the cancer clone cells – using our new drug ‘Valoxydin’ – it does not reduce the primary tumour size whatsoever, but we believe it does shut down the cascade of genetic and biochemical events that make metastasis possible. Metastasis is the main cause of death in Ewing and the reason why so much surgery is employed. Without the cancer metastasizing, life expectancy should dramatically increase. In theory, this should extend life expectancy.

Funded by the Trustees of the Charity, Brightwater is well equipped to do this research and is approaching the problem from the metastasis weakness in the cancer staging. At our own laboratory we have some very sophisticated facilities: we have organic synthetic chemistry including 400Mhz nuclear magnetic resonance spectrometry to make iterations of Valoxydin and we have a laboratory fully equipped for in vitro testing of the drug as we perform iterative modifications, including transcriptomic analysis. Animal model studies are outsourced and toxicity experiments are also undertaken by third party contract research organisations.

Our Trustees

Dr David Garnett
Fellow of the Royal Society of Biology, Member of the International Association for the Study of Lung Cancer, Member of the European Association for Metastasis Research.

David is our chief researcher and the driving force behind Brightwater. Prior to founding the organisation, he was the co-founder and Research Director for Pathway Intermediates Ltd, an industry leading animal nutrition company.

It is David’s deep expertise in cancer cell biology, cell culture, organic synthetic chemistry, transcriptomics and genomic analysis that continues to shape the direction of our ground breaking research.

Edward Youngman MScEcon, BScEcon

Ted is the Chief Operating Officer of Pathway Intermediates Ltd, . His background both as a COO and in prior roles overseeing governance and quality for a major British university, makes him a key member of the trustee board, ensuring that we apply management rigour at all times when running Brightwater.

Sonja Crane MEd, BSc (Hons), FHEA,RGN

With a lengthy career as a senior lecturer in university and hospice settings, Sonja continues to have a keen focus on palliative care and in improving the patient experience. Her engagement and familiarity with these topics, both as a nurse and subsequently in higher education, brings a strong understanding of the ‘human’ element of the impact of cancers to the board.

David Crane MCIPS, MBCS

Dave has a diverse background within IT and Service outsourcing, having worked on many of the world’s largest contracts as Commercial Director and subsequently as the global head of Innovation and emerging technologies for Hewlett Packard.

Dave brings commercial experience and a creative approach to problem solving.